What question did this study set out to answer?

This study aims to estimate the economic burden of leukemia diagnosis and treatment in South Africa.

May 22, 2026Leukemia ResearchOpen Access

Economic burden of leukemia diagnosis and treatment in South Africa: A retrospective cost of illness analysis

View Full Paper

Ask AI

Bookmark

Authors

Cost of illness analysis estimates significant leukemia treatment costs in South Africa, highlighting financial implications.

This study aims to estimate the economic burden of leukemia diagnosis and treatment in South Africa.
Conducted a cost of illness study over a 12-month period from diagnosis.
Utilized a bottom-up, incidence-based micro-costing approach to estimate costs.
Performed deterministic sensitivity analyses to assess parameter uncertainty.
The total annual economic burden of leukemia was estimated at $6 million, with direct costs of $4.5 million.
Average annual costs per patient ranged from $30,864 for acute lymphoblastic leukemia to $8,056 for chronic lymphocytic leukemia.
Direct costs accounted for 76.4% of total costs, approximately 0.03% of national healthcare expenditure.

Woudberg et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark